NO20021400D0 - Terapeutiske konazolinderivater - Google Patents
Terapeutiske konazolinderivaterInfo
- Publication number
- NO20021400D0 NO20021400D0 NO20021400A NO20021400A NO20021400D0 NO 20021400 D0 NO20021400 D0 NO 20021400D0 NO 20021400 A NO20021400 A NO 20021400A NO 20021400 A NO20021400 A NO 20021400A NO 20021400 D0 NO20021400 D0 NO 20021400D0
- Authority
- NO
- Norway
- Prior art keywords
- conazoline
- therapeutic
- derivatives
- therapeutic conazoline
- conazoline derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9922171.5A GB9922171D0 (en) | 1999-09-21 | 1999-09-21 | Chemical compounds |
PCT/GB2000/003593 WO2001021597A1 (en) | 1999-09-21 | 2000-09-19 | Therapeutic quinazoline derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20021400D0 true NO20021400D0 (no) | 2002-03-20 |
NO20021400L NO20021400L (no) | 2002-05-06 |
Family
ID=10861217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20021400A NO20021400L (no) | 1999-09-21 | 2002-03-20 | Terapeutiske kinazolinderivater |
Country Status (24)
Country | Link |
---|---|
US (1) | US7235559B1 (no) |
EP (1) | EP1218355A1 (no) |
JP (1) | JP2003509500A (no) |
KR (1) | KR20020030123A (no) |
CN (1) | CN1391563A (no) |
AR (1) | AR025735A1 (no) |
AU (1) | AU762697B2 (no) |
BG (1) | BG106526A (no) |
BR (1) | BR0014137A (no) |
CA (1) | CA2384296A1 (no) |
CO (1) | CO5200783A1 (no) |
CZ (1) | CZ20021008A3 (no) |
EE (1) | EE200200118A (no) |
GB (1) | GB9922171D0 (no) |
HK (1) | HK1046685A1 (no) |
HU (1) | HUP0300205A3 (no) |
IL (1) | IL148496A0 (no) |
IS (1) | IS6310A (no) |
NO (1) | NO20021400L (no) |
PL (1) | PL354870A1 (no) |
SK (1) | SK3872002A3 (no) |
TR (1) | TR200200717T2 (no) |
WO (1) | WO2001021597A1 (no) |
ZA (1) | ZA200202232B (no) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2305081T3 (es) | 2000-06-28 | 2008-11-01 | Astrazeneca Ab | Derivados de quinozolina sustituidos y su uso como inhibidores. |
AU2002217999A1 (en) | 2000-11-01 | 2002-05-15 | Cor Therapeutics, Inc. | Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides |
JP2002293773A (ja) * | 2001-03-30 | 2002-10-09 | Sumika Fine Chemicals Co Ltd | キナゾリン誘導体の製造方法 |
WO2003000188A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
WO2003035602A1 (fr) * | 2001-10-25 | 2003-05-01 | Sankyo Company, Limited | Modulateurs lipidiques |
PL211694B1 (pl) * | 2001-12-24 | 2012-06-29 | Astrazeneca Ab | Podstawiona pochodna chinazoliny, jej zastosowania oraz jej kompozycja farmaceutyczna |
BR0306982A (pt) | 2002-01-17 | 2004-10-26 | Neurogen Corp | Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, métodos para reduzir a condutância de cálcio de um receptor da capsaicina celular, para inibir a ligação de ligando vanilóide a um receptor da capsaicina in vitro e em um paciente, para tratar uma condição responsiva à modulação do receptor da capsaicina em um paciente, para tratar a dor em um paciente, para tratar coceira em um paciente, para tratar tosse ou soluço em um paciente, promover a perda de peso em um paciente obeso, e para determinar a presença ou ausência de receptor da capsaicina em uma amostra, preparação farmacêutica embalada, e, uso de um composto |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
US7176310B1 (en) | 2002-04-09 | 2007-02-13 | Ucb Sa | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents |
EP1548008A4 (en) * | 2002-08-23 | 2008-08-06 | Kirin Pharma Kk | COMPOUND HAVING BETA-TRANSFORMING GROWTH FACTOR INHIBITORY ACTIVITY AND DRUG CONTAINING COMPOSITION |
CA2503371C (en) | 2002-11-04 | 2011-01-11 | Astrazeneca Ab | Quinazoline derivatives as src tyrosine kinase inhibitors |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
RS20060097A (en) | 2002-12-20 | 2008-11-28 | Pfizer Products Inc., | Pyrimidine derivatives for the treatment of abnormal cell growth |
WO2004056812A1 (en) * | 2002-12-23 | 2004-07-08 | Astrazeneca Ab | 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents |
AU2003299943A1 (en) * | 2002-12-23 | 2004-07-22 | Ariad Pharmaceuticals, Inc. | Heterocycles and uses thereof |
WO2004056801A1 (en) * | 2002-12-23 | 2004-07-08 | Astrazeneca Ab | Quinazoline derivatives |
BRPI0317717B8 (pt) | 2002-12-24 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, e uso de um composto |
CA2508921A1 (en) | 2002-12-24 | 2004-07-15 | Astrazeneca Ab | Quinazoline compounds |
AU2003294142A1 (en) * | 2002-12-24 | 2004-07-22 | Astrazeneca Ab | Therapeutic quinazoline derivatives |
JP4709139B2 (ja) * | 2003-04-16 | 2011-06-22 | アストラゼネカ アクチボラグ | 癌の治療のためのキナゾリン誘導体 |
ES2308182T3 (es) * | 2003-06-02 | 2008-12-01 | Astrazeneca Ab | Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer. |
WO2004108707A1 (en) * | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | Pyridazinil quinazoline derivatives for use in the treatment of tumours |
WO2004108711A1 (en) * | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | Pyrazinil quinazoline derivatives for use in the treatment of tumours |
WO2004108710A1 (en) * | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | 4-pyrimidinyl quinazoline derivatives for use in the treatment of tumours |
TW200505452A (en) * | 2003-06-17 | 2005-02-16 | Astrazeneca Ab | Chemical compounds |
US7329664B2 (en) | 2003-07-16 | 2008-02-12 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
EP1660090B1 (en) * | 2003-08-14 | 2012-11-21 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
WO2005030140A2 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and methods of use |
DE602004022318D1 (de) * | 2003-10-14 | 2009-09-10 | Supergen Inc | Proteinkinaseinhibitoren |
US20090099165A1 (en) | 2003-10-14 | 2009-04-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
CA2540342A1 (en) * | 2003-10-31 | 2005-05-12 | Neurogen Corporation | 4-amino (aza) quinoline derivatives as capsaicin receptor agonists |
ES2315834T3 (es) | 2004-02-03 | 2009-04-01 | Astrazeneca Ab | Derivados de quinazolina. |
WO2005111016A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
WO2005111022A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidines derivatives for the treatment of abnormal cell growth |
WO2005111024A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
TW200624431A (en) | 2004-09-24 | 2006-07-16 | Hoffmann La Roche | Phthalazinone derivatives, their manufacture and use as pharmaceutical agents |
US7285569B2 (en) | 2004-09-24 | 2007-10-23 | Hoff Hoffmann-La Roche Inc. | Tricycles, their manufacture and use as pharmaceutical agents |
BRPI0516093A (pt) | 2004-10-12 | 2008-08-19 | Astrazeneca Ab | derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente |
WO2006044687A2 (en) | 2004-10-15 | 2006-04-27 | Takeda San Diego, Inc. | Kinase inhibitors |
EP1863792B1 (en) * | 2005-03-28 | 2009-01-21 | Brystol-Myers Squibb Company | Atp competitive kinase inhibitors |
JP2008535876A (ja) | 2005-04-14 | 2008-09-04 | エフ.ホフマン−ラ ロシュ アーゲー | アミノピラゾール誘導体、これらの製造、及び医薬製剤としての使用。 |
GB0509227D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
WO2007099323A2 (en) * | 2006-03-02 | 2007-09-07 | Astrazeneca Ab | Quinoline derivatives |
GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
MX2009007610A (es) | 2007-02-06 | 2009-07-24 | Boehringer Ingelheim Int | Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion. |
ES2470341T3 (es) | 2007-04-05 | 2014-06-23 | Amgen, Inc | Moduladores de la aurora cinasa y método de uso |
CN101215274B (zh) * | 2007-12-27 | 2011-05-04 | 上海北卡医药技术有限公司 | N取代吗啉类有机化合物的制备工艺 |
BRPI0907916A2 (pt) | 2008-02-07 | 2015-07-28 | Boehringer Ingelheim Int | Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos |
ES2413806T3 (es) | 2008-03-20 | 2013-07-17 | Amgen Inc. | Moduladores de la aurora cinasa y método de uso |
BRPI0912170A2 (pt) | 2008-05-13 | 2015-10-13 | Astrazeneca Ab | composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente |
CA2733153C (en) | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
WO2010019473A1 (en) | 2008-08-14 | 2010-02-18 | Amgen Inc. | Aurora kinase modulators and methods of use |
EP2340244A4 (en) * | 2008-10-14 | 2012-07-25 | Ning Xi | COMPOUNDS AND APPLICATION PROCEDURES |
EP2241565A1 (en) | 2009-01-15 | 2010-10-20 | Universität Leipzig | Aurora kinase inhibitors compounds |
NZ618004A (en) | 2009-01-16 | 2015-06-26 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
JP5583751B2 (ja) * | 2009-03-21 | 2014-09-03 | クイ ニング | アミノエステル誘導体、その塩、及び使用方法 |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
GB201021103D0 (en) * | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
CN103304489B (zh) * | 2012-03-16 | 2015-03-11 | 中国农业科学院兰州畜牧与兽药研究所 | 嘧啶苯甲酰胺类化合物及其制备和应用 |
MY191804A (en) | 2013-09-16 | 2022-07-15 | Astrazeneca Ab | Therapeutic polymeric nanoparticles and methods of making and using same |
AU2014373773C1 (en) | 2014-01-01 | 2019-06-27 | Medivation Technologies Llc | Compounds and methods of use |
EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
EP3939973A1 (en) | 2015-07-06 | 2022-01-19 | Alkermes, Inc. | Hetero-halo inhibitors of histone deacetylase |
EP3184507A1 (en) * | 2015-12-22 | 2017-06-28 | Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO | Preparation of phenyl compounds |
AU2018207402B2 (en) | 2017-01-11 | 2023-09-28 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
WO2019032528A1 (en) | 2017-08-07 | 2019-02-14 | Rodin Therapeutics, Inc | BICYCLIC HISTONE DEACETYLASE INHIBITORS |
CN110746398A (zh) * | 2019-10-18 | 2020-02-04 | 刘沛友 | 4-杂环取代喹唑啉类衍生物及其制备方法和用途 |
CN114436975B (zh) * | 2022-01-26 | 2023-10-31 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 2-三氟甲基-4-氨基喹唑啉类化合物及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
US6258820B1 (en) * | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
JP2002539262A (ja) * | 1999-03-19 | 2002-11-19 | パーカー ヒューズ インスティテュート | キナゾリン化合物製剤および治療におけるその使用 |
-
1999
- 1999-09-21 GB GBGB9922171.5A patent/GB9922171D0/en not_active Ceased
-
2000
- 2000-09-19 SK SK387-2002A patent/SK3872002A3/sk unknown
- 2000-09-19 TR TR2002/00717T patent/TR200200717T2/xx unknown
- 2000-09-19 EP EP00960850A patent/EP1218355A1/en not_active Withdrawn
- 2000-09-19 IL IL14849600A patent/IL148496A0/xx unknown
- 2000-09-19 KR KR1020027003680A patent/KR20020030123A/ko not_active Application Discontinuation
- 2000-09-19 EE EEP200200118A patent/EE200200118A/xx unknown
- 2000-09-19 BR BR0014137-2A patent/BR0014137A/pt not_active IP Right Cessation
- 2000-09-19 CZ CZ20021008A patent/CZ20021008A3/cs unknown
- 2000-09-19 PL PL00354870A patent/PL354870A1/xx not_active Application Discontinuation
- 2000-09-19 US US10/088,856 patent/US7235559B1/en not_active Expired - Fee Related
- 2000-09-19 CN CN00816012A patent/CN1391563A/zh active Pending
- 2000-09-19 AU AU73019/00A patent/AU762697B2/en not_active Ceased
- 2000-09-19 JP JP2001524976A patent/JP2003509500A/ja active Pending
- 2000-09-19 WO PCT/GB2000/003593 patent/WO2001021597A1/en not_active Application Discontinuation
- 2000-09-19 HU HU0300205A patent/HUP0300205A3/hu unknown
- 2000-09-19 CA CA002384296A patent/CA2384296A1/en not_active Abandoned
- 2000-09-21 AR ARP000104956A patent/AR025735A1/es unknown
- 2000-09-21 CO CO00071838A patent/CO5200783A1/es not_active Application Discontinuation
-
2002
- 2002-03-18 BG BG106526A patent/BG106526A/xx unknown
- 2002-03-19 ZA ZA200202232A patent/ZA200202232B/en unknown
- 2002-03-19 IS IS6310A patent/IS6310A/is unknown
- 2002-03-20 NO NO20021400A patent/NO20021400L/no unknown
- 2002-11-19 HK HK02108371.0A patent/HK1046685A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CO5200783A1 (es) | 2002-09-27 |
EP1218355A1 (en) | 2002-07-03 |
IS6310A (is) | 2002-03-19 |
BG106526A (en) | 2002-10-31 |
CZ20021008A3 (cs) | 2002-06-12 |
TR200200717T2 (tr) | 2002-06-21 |
SK3872002A3 (en) | 2002-12-03 |
KR20020030123A (ko) | 2002-04-22 |
HUP0300205A2 (en) | 2003-05-28 |
US7235559B1 (en) | 2007-06-26 |
PL354870A1 (en) | 2004-03-08 |
JP2003509500A (ja) | 2003-03-11 |
HUP0300205A3 (en) | 2003-08-28 |
WO2001021597A1 (en) | 2001-03-29 |
CA2384296A1 (en) | 2001-03-29 |
ZA200202232B (en) | 2003-08-27 |
IL148496A0 (en) | 2002-09-12 |
NO20021400L (no) | 2002-05-06 |
AR025735A1 (es) | 2002-12-11 |
GB9922171D0 (en) | 1999-11-17 |
CN1391563A (zh) | 2003-01-15 |
BR0014137A (pt) | 2002-05-21 |
EE200200118A (et) | 2003-04-15 |
HK1046685A1 (zh) | 2003-01-24 |
AU7301900A (en) | 2001-04-24 |
AU762697B2 (en) | 2003-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20021400D0 (no) | Terapeutiske konazolinderivater | |
DK1637127T3 (da) | Terapeutisk mikroskum | |
IS2277B (is) | Meðferðarlegar bíarýl afleiður | |
IS2116B (is) | 4-fenyl-pyridin afleiður | |
NO20021077L (no) | Amino-triazolopyridin-derivater | |
DE60009747D1 (de) | Admantan-derivate | |
ATE293104T1 (de) | Thiazolylamid-derivate | |
PT1235558E (pt) | Agentes terapeuticos | |
IS6128A (is) | 13-Metýl-erýþrómýsín afleiður | |
DK1187814T3 (da) | 5-phenyl-pyrimidinderivater | |
ATE338021T1 (de) | Substituierte 2-dialkylaminoalkylbiphenyl- derivate | |
NO20021803L (no) | Isoksazolkarboksamid-derivater | |
PT1237857E (pt) | Novos derivados fenalquiloxi-fenilo | |
ATE257148T1 (de) | Propargyletherderivate | |
DK1154988T3 (da) | Mevinolinderivater | |
ATE374747T1 (de) | Monofluoralkylderivate | |
DE60006703D1 (de) | 4-hydroxybiphenylhydrazid-derivate | |
DK1187815T3 (da) | 4-phenyl-pyrimidinderivater | |
ATE293592T1 (de) | Resorcinderivate | |
DE60025348D1 (de) | Ethansulfonyl-piperidin-derivate | |
NO20022867D0 (no) | Syklopentenon-derivater | |
NO20020212D0 (no) | 3-amino-2-benzyl-1-fenyl-propanderivater | |
TR200002831A3 (tr) | Kinolin-4-Il türevleri I | |
DE60001736D1 (de) | 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate | |
NO20016301D0 (no) | Terapeutiske midler |